000 05404cam a2200577Ma 4500
001 ocn911246573
003 OCoLC
005 20190328114811.0
006 m o d
007 cr cnu---unuuu
008 150620s2015 ne o 001 0 eng d
040 _aEBLCP
_beng
_epn
_cEBLCP
_dOPELS
_dE7B
_dUIU
_dUV0
_dOCLCF
_dOCLCQ
_dBUF
_dOCLCO
_dMERER
_dOCLCO
_dOCLCQ
_dU3W
_dOCLCO
_dD6H
_dUKMGB
_dWYU
_dOCLCO
_dOCLCA
015 _aGBB6G6316
_2bnb
016 7 _a018086898
_2Uk
020 _z9780444626493
020 _z0444626492
020 _z9780444626677
020 _z0444626670
035 _a(OCoLC)911246573
050 4 _aRC271.C5
082 0 4 _a616.994061
100 1 _aAvenda�no, Carmen.
245 1 0 _aMedicinal chemistry of anticancer drugs /
_h[electronic resource]
_cby Carmen Avenda�no and J. Carlos Men�endez.
250 _a2nd ed.
260 _aAmsterdam :
_bElsevier Science,
_c2015.
300 _a1 online resource (767 pages)
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
588 0 _aPrint version record.
500 _aIncludes index.
520 _aMedicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year.
505 0 _aFront Cover; Medicinal Chemistry of Anticancer Drugs; Copyright; Contents; Foreword; Preface; Abbreviations; Chapter 1: General Aspects of Cancer Chemotherapy; 1. Introduction: Some General Comments About Cancer; 2. Tumorigenesis and Oncogenes: Pharmacogenomics; 3. Early Diagnosis of Cancer and Its Therapeutic Relevance; 4. A Brief History of Cancer Chemotherapy; 5. General Comments About Anticancer Drug Discovery; 6. Combination Therapy and Personalized Anticancer Treatments; 7. Natural Products in Cancer Chemotherapy; 8. A Brief Comment About Cancer Nanotechnology.
505 8 _a9. Summary of FDA-Approved Anticancer DrugsReferences; Chapter 2: Antimetabolites That Interfere with Nucleic Acid Biosynthesis; 1. Introduction; 2. Inhibitors of the Biosynthesis of Uridylic Acid; 3. Inhibitors of Ribonucleotide Reductase; 3.1. Structure and Catalytic Cycle of Ribonucleotide Reductase; 3.2. Gallium Salts and Complexes; 3.3. Radical Scavengers; 3.4. Substrate Analogs as Ribonucleotide Reductase Inhibitors; 3.5. Allosteric Inhibition of Ribonucleotide Reductase via Inhibition of Purine Nucleoside Phosphorylase; 4. Inhibitors of the Biosynthesis of Thymidilic Acid.
505 8 _a4.1. Thymidylate Synthase4.2. 5-Fluorouracil and Floxuridine; 4.3. 5-Fluorouracil Prodrugs; 4.4. Modulation of 5-Fluorouracil Activity; 4.4.1. Decreased Degradation of 5-FU; 4.4.2. Enhancement of the Inhibition of Thymidylate Synthase by 5-FU; 4.4.3. Enhancement of 5-FU Activation; 4.5. Trifluridine; 4.6. Folate-Based Thymidylate Synthase Inhibitors; 5. Inhibitors of Dihydrofolate Reductase; 5.1. Classical DHFR Inhibitors; 5.2. Nonclassical (Lipophilic) DHFR Inhibitors; 6. Inhibitors of the De Novo Purine Biosynthesis Pathway; 6.1. Inhibitors of PRPP Amidotransferase.
505 8 _a6.2. Inhibitors of Glycinamide Ribonucleotide Formyltransferase6.3. Inhibitors of Phosphoribosylformylglycinamidine Synthetase; 6.4. Inhibitors of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase; 6.5. Thiopurines and Related Compounds; 7. Inhibitors of Adenosine Deaminase; 8. Inhibitors of Late Stages in DNA Synthesis; 8.1. Pyrimidine Nucleosides; 8.2. Purine Nucleosides; 9. Antimetabolite Enzymes; References; Chapter 3: Anticancer Drugs That Modulate Hormone Action; 1. Introduction; 2. Estrogens and Their Involvement in Carcinogenesis; 3. Antiestrogens as Antitumor Drugs.
505 8 _a3.1. Nonsteroidal Antiestrogens (Selective Estrogen Receptor Modulators)3.2. Steroidal Antiestrogens; 4. Aromatase Inhibitors; 4.1. Aromatase Mechanism of Action; 4.2. Steroidal Aromatase Inhibitors (Type I Inhibitors); 4.3. C-19 Modified Substrate Analogs; 4.4. 4-Hydroxyandrostenedione Derivatives; 4.5. Steroids with Additional Unsaturations at the A and B Rings; 4.6. Structure-Activity Relationships in Steroidal Aromatase Inhibitors; 4.7. Nonsteroidal Aromatase Inhibitors (Type II); 5. Steroid Sulfatase Inhibitors; 6. Androgen-Related Antitumor Agents; 6.1. Antiandrogens.
650 0 _aCancer
_xChemotherapy.
650 0 _aDrugs
_xDesign.
650 0 _aPharmaceutical chemistry.
650 7 _aCancer
_xChemotherapy.
_2fast
_0(OCoLC)fst00845327
650 7 _aDrugs
_xDesign.
_2fast
_0(OCoLC)fst00898790
650 7 _aPharmaceutical chemistry.
_2fast
_0(OCoLC)fst01060115
650 2 _aNeoplasms
_xtherapy.
_0(DNLM)D009369Q000628
650 2 _aDrug Design.
_0(DNLM)D015195
650 2 _aChemistry, Pharmaceutical.
_0(DNLM)D002626
655 4 _aElectronic books.
700 1 _aMen�endez, J. Carlos
_q(Jos�e Carlos)
776 0 8 _iPrint version:
_aAvendano, Carmen.
_tMedicinal Chemistry of Anticancer Drugs.
_dBurlington : Elsevier Science, �2015
_z9780444626493
856 4 0 _3ScienceDirect
_uhttp://www.sciencedirect.com/science/book/9780444626493
999 _c247106
_d247106